Filter posts

ICYMI: Jim Greenwood’s Letter in NYT on Drug Importation

Yesterday, the New York Times published a letter to the editor from BIO’s President and …

ICYMI – NYT: The Cost of Not Taking Your Medicine

We’ve long known that prescription medicines can yield substantial savings in other areas of healthcare …

Latest New York Times Report On Patents and Drug Prices Misses The Mark

BIO is committed not only to reminding the public about the value of innovation and …

NYT Misses the Point on Yields, Pesticides and What Farmers Need

Industry experts, academics, farmers and growers have plenty to say about an October 30 article …

WSJ: A Piece of the Immunotherapy Puzzle Solved

Just two weeks ago, the New York Times published a series of articles deeming immunotherapy …

ICYMI: NYT Chronicles Advances in Cancer Landscape Due to Immunotherapy

This week, the New York Times published a series of articles titled Cell Wars which explores …

FOIA Attacks Against Biotech Scientists Get Personal

Much has been written and discussed online about the relationships between independent researchers and industry …

Ezekiel Emanuel's Flawed Solution

In a New York Times op-ed today, Dr. Ezekiel Emanuel proposes “The Solution to Drug …

Jim Greenwood in New York Times: Specialty Tiers Limit Patient Access

Today, the New York Times published a letter from Jim Greenwood, BIO’s President and CEO. …

Why the Founder of the Anti-GMO Movement Converted to the Side of Science

Mark Lynas is a researcher at the Cornell Alliance for Science and the author, most …